Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cinnarizine + dimenhydrinate
- Development stage
- Unknown
- Lead developer
- Henning Arzneimittel
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Cinnarizine + dimenhydrinate is a fixed-dose combination of two small molecule drugs used primarily for the treatment of vertigo in adults. Cinnarizine acts as a calcium channel antagonist, improving microcirculation in the inner ear and acting as a vestibular sedative by inhibiting calcium influx into vestibular sensory cells. Dimenhydrinate is an antihistamine with anticholinergic (antimuscarinic) properties, exerting antiemetic and antivertiginous effects mainly through central inhibition of histamine H1 receptors and muscarinic acetylcholine receptors. The combination provides both peripheral (cinnarizine) and central (dimenhydrinate) effects on the vestibular system, resulting in synergistic efficacy for vertigo symptoms such as dizziness, nausea, vomiting, and spinning sensation. It is considered more effective than either component alone for vertigo of various origins[1][2][3][4][5][6][8].
- Brand names
- CizinateArlevertStugeron PlusVertigenGemvertDiziron DVomivertDizilivVertidizCimenzaStugil D
- Other names
- cinnarizine/dimenhydrinate
02
Targets
M1 (Muscarinic acetylcholine receptor M1)HRH1 (Histamine H1 Receptor)CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)
Beyond the preview
Go deeper on cinnarizine + dimenhydrinate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cinnarizine + dimenhydrinate.